A Colorado biotech ends clinical work to focus on marketing ADHD drug, consumer health products
A biopharma that markets an ADHD medication, and sells a portfolio of over-the-counter consumer health products on Amazon and elsewhere, has decided to scrap all work on clinical-stage assets.
The Englewood, CO-based biotech will do away with a global Phase III trial that had begun just three months ago. The goal was to test enzastaurin, or AR101, as a treatment for patients with a certain type of Vascular Ehlers-Danlos syndrome, which can weaken the aorta and other arteries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.